Promentis
researches, develops and commercializes novel therapies for the treatment of central nervous system disorders... Read morePromentis
researches, develops and commercializes novel therapies for the treatment of central nervous system disorders... Read more
News
Oct 31, 2020
Markets Insider
Promentis: Promentis Pharmaceuticals to Present at the 11th Anniversary CNS Summit | Markets Insider
Dec 10, 2019
SEC
Promentis: Promentis has Received $2.5M in Debt Funding
Nov 02, 2019
Pharmabiz
Promentis Pharmaceuticals: Promentis Pharma announces positive results for phase 2A study of SXC─2023 targeting novel glutamatergic mechanism and completion of enrollment for phase 2 trichotillomania study
Nov 01, 2019
MarketScreener
Promentis Pharmaceuticals: Promentis Pharmaceuticals to Present at the 10th Anniversary CNS Summit
May 02, 2019
BizTimes
Promentis Pharmaceuticals: Promentis progressing down long pharmaceutical road
Feb 18, 2019
BizTimes
Promentis Pharmaceuticals: Promentis Pharmaceuticals enters Phase 2 trials for impulse control drug
Jan 21, 2019
BioPortfolio
Promentis Pharmaceuticals: Promentis Pharmaceuticals commences phase 2 studies for SXC2023 targeting novel Glutamatergic mechanism
Jan 21, 2019
Pharmaceutical Business Review
Promentis Pharmaceuticals: Promentis Pharmaceuticals commences phase 2 studies for SXC-2023 targeting novel Glutamatergic mechanism
Dec 05, 2018
PR Newswire
Press Release: Promentis Pharmaceuticals : Promentis Pharmaceuticals to present at the 57th annual American College of Neuropsychopharmacology (ACNP) meeting
Nov 16, 2018
4-traders
Promentis Pharmaceuticals: Promentis Pharmaceuticals Announces Successful Completion of Phase 1 Studies for SXC-2023 Targeting Novel Glutamatergic Mechanism
Promentis Competitors
1
2
3
4
5
6
7
8
9
10